



# AI for Obesity Research and Clinical Practice

Credit for this course may not exceed 3.5 credit when both the live and enduring material activity format credits are combined.

## Live Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this live activity for a maximum of **3.5 AMA PRA Category 1 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*ACCME Activity ID 202790169*

## On-Demand Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of **3.5 AMA PRA Category 1 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*ACCME Activity ID 202790170*

## Important Dates for On-Demand Course (Enduring Material)

Date of Release: January 1, 2025

Date of Termination: December 31, 2027

# Learning Objectives

1. Learners will be able to explain what successful multi-site AI obesity projects and clinical practice tools look like.
2. Learners will be able to phrase clinical research questions in ways that AI requires to be able to perform tasks.
3. Learners will understand how to make data AI-ready.
4. Learners will understand timelines and workload to develop, train, validate, and execute AI algorithms.
5. Learners will be able to classify and recruit AI-trained collaborators to work on projects.

# Commercial Support

No commercial support was received for this activity.

# Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity - including faculty, planners, reviewers or others - are required to disclose all financial relationships with ineligible entities<sup>1</sup> (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all financial relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate financial relationships. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed.

## Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker).

## Panelists:

Note: there are no panelists in this activity. Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below.

---

<sup>1</sup> An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that “The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased.”

### Speaker Disclosures:

Chirra, Prathyush, PhD	No relevant financial relationships
Clark, Nicholas, PhD	No relevant financial relationships
Dhurandhar, Nikhil, MS, LCEH, PhD, FTOS	Advisor relationship with Medifast (Medical Food). Researcher relationship with Novo Nordisk (Pharmaceuticals).
Hartshorn, Christopher, PhD	No relevant financial relationships
Redman, Leanne, PhD, FTOS	No relevant financial relationships
Thomas, Diana, PhD, FTOS	No relevant financial relationships

### Planner Disclosures:

Redman, Leanne, PhD, FTOS	No relevant financial relationships
Thomas, Diana, PhD, FTOS	No relevant financial relationships

**Reviewer Disclosures:** No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

## Bibliography

1. Transforming Big Data into AI-ready data for nutrition and obesity research, *Obesity* 2024.
2. Accreditation Board for Engineering and Technology (ABET) Criteria for Accrediting Computing Programs, 2023 – 2024 [https://www.abet.org/wp-content/uploads/2023/05/C001\\_CAC-Criteria\\_2023-2024.pdf](https://www.abet.org/wp-content/uploads/2023/05/C001_CAC-Criteria_2023-2024.pdf)
3. Wu E, Wu K, Daneshjou R, Ouyang D, Ho DE, Zou J. How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals. *Nature Medicine*. 2021;27(4):582-584.
4. Shao D, Dai Y, Li N, et al. Artificial intelligence in clinical research of cancers. *Briefings in Bioinformatics*. 2021;23(1).
5. Thomas DM, Kleinberg S, Brown AW, Crow M, Bastian ND, Reisweber N, Lasater R, Kendall T, Shafto P, Blaine R, Smith S, Ruiz D, Morrell C, Clark N. Machine learning modeling practices to support the principles of AI and ethics in nutrition research. *Nutr Diabetes*. 2022 Dec 2;12(1):48.

## Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness,

noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

*This document was last updated October 2, 2024.*